진행성 미분화 림프구성 림프종(DPDL) 및 미만성 조직구성 림프종(DHL)에 대한 복합화학요법 = Combination Chemotherapy of Advanced Diffuse Poorly Differentiated Lymphocytic Lymphoma(DPDL) and Diffuse Histiocytic Lymphoma(DHL)

다국어 초록 (Multilingual Abstract)

Fifteen patients with stage Ⅲ or Ⅳ diffuse histiocytic lymphoma(DHL) and diffuse poorly differentiated lymphocytic lymphoma(DPDL) were treated with cyclophosphamide, doxorubicin, vincristine and prednisolone(CHOP) and other combination chemotherapy regimen, such as IMVP, C-MOPP and CVP regimen.
Seven patients (47%) achieved complete remission and and three patients (20%) obtained partial remission. The overall response rate was 67%(10/15). Among eleven patients treated with CHOP regimen, six patients (54.5%) achieved complete remission. In eight patients with DHL three patients (37.5%) obtained complete remission and in seven patients with DPDL, four patients (57.1%) achieved complete remission.
The median duration of remission was 9+ months (range; 2+ - 34+ months). The median duration of survival was 13+ months (range; 6+ - 36+ months).
The incidence of hematologic toxicities following the chemotherapy were evaluated by ECOG toxicity criteria. The severe heamtologic toxicities(grade Ⅲ or Ⅳ) after the 133 cycles of treatment were as followings, anemia 13%, leukopenia 13% and thrombocytopenia 7%.
The therapeutic effects of involving CHOP regimen as the mainstay for therapy of the advanced DHL and DPDL including CHOP and other regimen was substantial. The further elucidation of therapeutic uses of such first or second line regimen, we need more patient accrual and further prognostic stratification of subjects.